biote (BTMD) Q4 2024 earnings summary

Executive summary

• Announced new CEO Bret Christensen, highlighting his healthcare leadership and focus on commercial execution and growth initiatives.

• Revenue for Q4 2024 was $49.8M, up 9% year-over-year; full year revenue reached $197.2M, up 6.4%.

• Gross profit margin improved to 71.8% in Q4 and 70.5% for the year, driven by vertical integration and cost management.

• Net income for Q4 was $3.5M ($0.10 per diluted share); full year net income was $0.05M (diluted EPS $0.09), reversing a prior year loss.

• Launched and completed rollout of upgraded clinical decision support software (CDSS) and BioTRX/BioteRx wellness platform, enhancing practitioner and patient experience.

Financial highlights

• Q4 2024 revenue was $49.8 million, up 9% year-over-year; procedure revenue grew 5%, dietary supplement revenue up 10.2%.

• Gross profit margin for Q4 was 71.8%, a 247 basis point increase from Q4 2023, driven by cost savings from vertical integration.

• Net income for Q4 was $3.5 million ($0.10 per diluted share), down from $12.1 million ($0.18 per share) in Q4 2023, reflecting changes in fair value of earn-out liabilities.

• Adjusted EBITDA rose 11.4% to $15.1 million (margin 30.3%), compared to $13.6 million (margin 29.7%) in Q4 2023; full year Adjusted EBITDA was $58.2M (29.5% margin).

• Cash flow from operations for FY 2024 was $45.2 million, up from $26.9 million in FY 2023; cash and equivalents at year-end were $39.3 million.

Outlook and guidance

• 2025 revenue expected at $202–$208 million; adjusted EBITDA forecasted at $59–$64 million.

• Procedure revenue projected to grow 2–4% and dietary supplement revenue 5–10% year-over-year in 2025.

• Q1 2025 revenue expected to be slightly higher than Q1 2024, but adjusted EBITDA to be ~5% lower due to increased sales and marketing investments.

• Strategic focus on maximizing top-tier providers, expanding practitioner network, and improving commercial execution.